JPH08504090A - 抗−ネコ免疫不全ウイルス(fiv)ワクチン - Google Patents
抗−ネコ免疫不全ウイルス(fiv)ワクチンInfo
- Publication number
- JPH08504090A JPH08504090A JP6507935A JP50793594A JPH08504090A JP H08504090 A JPH08504090 A JP H08504090A JP 6507935 A JP6507935 A JP 6507935A JP 50793594 A JP50793594 A JP 50793594A JP H08504090 A JPH08504090 A JP H08504090A
- Authority
- JP
- Japan
- Prior art keywords
- fiv
- polypeptide
- sequence
- nucleic acid
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title abstract description 37
- 241000700605 Viruses Species 0.000 title description 24
- 206010061598 Immunodeficiency Diseases 0.000 title description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 title description 2
- 230000007813 immunodeficiency Effects 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 180
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 146
- 229920001184 polypeptide Polymers 0.000 claims abstract description 96
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 18
- 101710188315 Protein X Proteins 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 230000000890 antigenic effect Effects 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000013599 cloning vector Substances 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 108700004025 env Genes Proteins 0.000 claims 3
- 101150030339 env gene Proteins 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 19
- 241000713800 Feline immunodeficiency virus Species 0.000 description 103
- 241000282326 Felis catus Species 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- -1 amino acid sequence Compounds Chemical class 0.000 description 12
- 238000010241 blood sampling Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
- 241000282324 Felis Species 0.000 description 8
- 230000002788 anti-peptide Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000702673 Bovine rotavirus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000709691 Enterovirus E Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233756 Fabriciana elisa Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710099276 Probable metalloendopeptidase Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 208000010949 lymph node disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記のアミノ酸配列: FIVエンベロープタンパク質 から選択されたアミノ酸配列の全部または一部を含む合成ポリペプチド、あるい はその抗原性フラグメント、機能的に等価な変異体または薬理的に許容される塩 。 2.FIVの防除に使用するための、請求項1に記載の合成ポリペプチド。 3.前記アミノ酸配列に融合した追加のポリペプチドを含む融合タンパク質の形 態にあるか、あるいは担体タンパク質またはポリペプチドに結合されている、請 求項1または請求項2に記載の合成ポリペプチド。 4.請求項1〜3の何れかで定義された合成ポリペプチドの、FIV防除用組成物 の製造における使用。 5.FIV防除用組成物の製造に使用するための、下記の酸基: 残基 (1) 377-417;および/または (2) 462-490;および/または (3) 354-377;および/または (4) 302-320;および/または (5) 417-445;および/または (6) 320-339;および/または (7) 161-190;および/または (8) 248-267;および/または (9) 601-620;および/または (10) 716-736; から選択された、FIVエンベロープタンパク質のFIV env遺伝子をコードする残基 の領域の全部または一部を含むヌクレオチド配列を含むか、あるいはこのような 上記配列の何れかの変性物である配列、上記配列の何れかと実質的に相同性の配 列、または上記配列の何れかとハイブリッド化する配列を含む核酸分子。 6.下記の残基: 残基 (1) 377-417;および/または (2) 462-490;および/または (3) 354-377;および/または (4) 302-320;および/または (5) 417-445;および/または (6) 320-339;および/または (7) 161-190;および/または (8) 248-267;および/または (9) 601-620;および/または (10) 716-736; から選択された、FIVエンベロープタンパク質のFIV env遺伝子をコードする残基 の領域の全部または一部に実質的に対応する第一ヌクレオチド配列、あるいはこ のような上記配列の何れかの変性物である配列、上記配列の何れかと実質的に相 同性の配列、または上記配列の何れかとハイブリッド化する配列を、上記第一ヌ クレオチド配列の側部にある少なくとも1つの追加のヌクレオチド配列と一緒に 含み、この追加のヌクレオチド配列が900個以下の塩基を含む、核酸分子。 7.請求項5または請求項6で定義された核酸分子の、FIV防除用組成物の製造 における使用。 8.下記の残基: (1) 377-417;および/または (2) 462-490;および/または (3) 354-377;および/または (4) 302-320;および/または (5) 417-445;および/または (6) 320-339;および/または (7) 161-190;および/または (8) 248-267;および/または (9) 601-620;および/または (10) 716-736; から選択された、FIVエンベロープタンパク質のFIV env遺伝子をコードす る残基の領域からの1個または数個の抗原決定基-コード領域を組み込んでいる か、あるいはこのような上記配列の何れかの変性物である配列、上記配列の何れ かと実質的に相同性の配列、または上記配列の何れかとハイブリッド化する配列 を組み込んでいる、FIVに対する中和抗体を産生しうるポリペプチドをコードす るヌクレオチド配列を含む核酸分子の使用。 9.請求項5で定義されたヌクレオチド配列を含む核酸分子を含む発現ベクター またはクローニングベクター。 10.請求項5で定義されたヌクレオチド配列を含む核酸分子を含有するか、あ るいは請求項9に記載の発現ベクターを含有する宿主細胞またはトランスジェニ ック微生物。 11.請求項10で定義された宿主細胞を、請求項1〜3の何れかで定義された 合成ポリペプチドが発現される条件下で培養し、こうして生成した上記ポリペプ チドを回収することからなる、請求項1〜3の何れかで定義された合成ポリペプ チドの製造方法。 12.対応する保護されたポリペプチドまたは固定化されたポリペプチドを、保 護基の脱離または固体支持体からの分離に付することからなる、請求項1〜3の 何れかで定義された合成ポリペプチドの製造方法。 13.請求項1〜3の何れかで定義された合成ポリペプチドの1種または数種、 あるいは請求項5で定義されたヌクレオチド配列を含む核酸分子が挿入されてお り、挿入された核酸分子によりコードされるポリペプチドに対する免疫応答を刺 激するための発現ベクターまたは宿主細胞の1種または数種を、薬理的に許容さ れる担体または希釈剤と一緒に含む、FIV防除用組成物。 14.1種または数種の他の抗原性FIVタンパク質および/またはポリペプ チドを更に含有する、請求項13に記載の組成物。 15.請求項13または請求項14に記載の組成物を動物に投与することからな る、動物におけるFIVを防除する方法。 16.請求項1〜3の何れかで定義された合成ポリペプチドに結合することので きる抗体。 17.請求項1〜3の何れかで定義された合成ポリペプチドの1種または数種を 、FIVに対する抗体を含むサンプルと接触させ、上記ポリペプチドと上記抗体と の間で形成された複合体の存在を検出することからなる、FIVに対する抗体の検 出方法。 18.請求項1〜3の何れかで定義された合成ポリペプチドの1種または数種、 および上記ポリペプチドと上記抗体との間で形成された複合体を検出するための 手段を含む、サンプル中のFIVに対する抗体を検出するための試験キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929219936A GB9219936D0 (en) | 1992-09-21 | 1992-09-21 | Vaccines |
GB9219936.3 | 1992-09-21 | ||
PCT/GB1993/001974 WO1994006471A1 (en) | 1992-09-21 | 1993-09-20 | Anti-feline immunodeficiency virus (fiv) vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08504090A true JPH08504090A (ja) | 1996-05-07 |
JP3604384B2 JP3604384B2 (ja) | 2004-12-22 |
Family
ID=10722245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50793594A Expired - Fee Related JP3604384B2 (ja) | 1992-09-21 | 1993-09-20 | 抗−ネコ免疫不全ウイルス(fiv)ワクチン |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0661999B1 (ja) |
JP (1) | JP3604384B2 (ja) |
AT (1) | ATE175119T1 (ja) |
AU (1) | AU4826493A (ja) |
DE (1) | DE69322872T2 (ja) |
DK (1) | DK0661999T3 (ja) |
ES (1) | ES2127294T3 (ja) |
GB (1) | GB9219936D0 (ja) |
GR (1) | GR3029264T3 (ja) |
WO (1) | WO1994006471A1 (ja) |
ZA (1) | ZA936970B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995030019A1 (en) * | 1994-04-29 | 1995-11-09 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
IT1276509B1 (it) * | 1995-03-31 | 1997-10-31 | Istituto Superiore Della Sanit | Vaccino per la profilassiimmunitaria dell'infezione da virus della immunodeficienza felina del gatto domestico. |
US5849303A (en) * | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US6300118B1 (en) | 1995-06-07 | 2001-10-09 | American Home Products Corporation | Plasmids comprising a genetically altered feline immunodeficiency virus genome |
DE69634820T2 (de) * | 1995-08-25 | 2006-03-23 | University of Florida Research Foundation, Inc., Gainesville | Impfstoff gegen mehrere fiv-subtypen |
FR2769916B1 (fr) * | 1997-10-17 | 2000-12-01 | Centre Nat Rech Scient | Peptides issus du gene env du virus de l'immunodeficience feline et leurs applications immunoprotectrices et vaccinales |
FR2771011B1 (fr) * | 1997-11-17 | 2000-01-28 | Hippocampe | Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale |
GB9827077D0 (en) | 1998-12-09 | 1999-02-03 | Expro North Sea Ltd | Improvements in or relating to well fluid sampling |
WO2001004280A2 (de) * | 1999-07-08 | 2001-01-18 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze |
FR2828687B1 (fr) * | 2001-08-17 | 2003-12-12 | Hippocampe | Nouveaux peptides et leur utilisation comme medicaments contre l'infection par le fiv chez le chat |
FR2828686B1 (fr) * | 2001-08-17 | 2003-12-12 | Hippocampe | Nouveaux peptides et leur utilisation comme medicaments contre l'infection par le fiv chez le chat |
WO2006011919A1 (en) | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
ATE435425T1 (de) | 2003-09-11 | 2009-07-15 | Idexx Lab Inc | Verfahren zum nachweis des felinen immunschwächevirus |
AU2004304348B2 (en) | 2003-12-18 | 2009-02-26 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2005080939A2 (en) * | 2004-02-19 | 2005-09-01 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2006011920A1 (en) | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
US7291338B2 (en) | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2011123781A1 (en) | 2010-04-02 | 2011-10-06 | Idexx Laboratories, Inc. | Detection of feline immunodeficiency virus |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2669338A1 (fr) * | 1990-11-21 | 1992-05-22 | Centre Nat Rech Scient | Fragments peptidiques issus de la proteine externe du vif, anticorps antifragments, application de ceux-ci au diagnostic et/ou au traitement de l'immunodeficience feline. |
US6228608B1 (en) * | 1991-02-28 | 2001-05-08 | Aquila Biopharmaceuticals, Inc. | Recombinant FIV glycoprotein 160 and P24 gag protein |
AU667669B2 (en) * | 1991-06-14 | 1996-04-04 | Idexx Laboratories, Inc. | Detection of mammalian immunodeficiency viruses |
WO1993001304A1 (en) * | 1991-07-10 | 1993-01-21 | Synbiotics Corporation | Synthetic peptides related to fiv-env proteins |
-
1992
- 1992-09-21 GB GB929219936A patent/GB9219936D0/en active Pending
-
1993
- 1993-09-20 EP EP93920971A patent/EP0661999B1/en not_active Expired - Lifetime
- 1993-09-20 DK DK93920971T patent/DK0661999T3/da active
- 1993-09-20 JP JP50793594A patent/JP3604384B2/ja not_active Expired - Fee Related
- 1993-09-20 AT AT93920971T patent/ATE175119T1/de not_active IP Right Cessation
- 1993-09-20 AU AU48264/93A patent/AU4826493A/en not_active Abandoned
- 1993-09-20 ES ES93920971T patent/ES2127294T3/es not_active Expired - Lifetime
- 1993-09-20 DE DE69322872T patent/DE69322872T2/de not_active Expired - Lifetime
- 1993-09-20 WO PCT/GB1993/001974 patent/WO1994006471A1/en active IP Right Grant
- 1993-09-21 ZA ZA936970A patent/ZA936970B/xx unknown
-
1999
- 1999-02-01 GR GR990400341T patent/GR3029264T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU4826493A (en) | 1994-04-12 |
ATE175119T1 (de) | 1999-01-15 |
EP0661999A1 (en) | 1995-07-12 |
ES2127294T3 (es) | 1999-04-16 |
EP0661999B1 (en) | 1998-12-30 |
WO1994006471A1 (en) | 1994-03-31 |
DE69322872T2 (de) | 1999-05-27 |
DK0661999T3 (da) | 1999-08-30 |
JP3604384B2 (ja) | 2004-12-22 |
DE69322872D1 (de) | 1999-02-11 |
GR3029264T3 (en) | 1999-05-28 |
GB9219936D0 (en) | 1992-11-04 |
ZA936970B (en) | 1994-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08504090A (ja) | 抗−ネコ免疫不全ウイルス(fiv)ワクチン | |
RU2201421C2 (ru) | Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител | |
JP2003529319A (ja) | HIV−1gp41を標的化する広範に中和する抗体を誘発する方法 | |
US5840313A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
JP2001502658A (ja) | 非樹状中心骨格ペプチド担体 | |
JPH03502687A (ja) | レスピラトリイ・シンシチアル・ウイルス:ワクチンおよび診断法 | |
KR20010053042A (ko) | 구제역에 대한 합성 펩티드 백신 | |
JPH05262667A (ja) | ウイルス抗原を用いるワクチン | |
KR101121754B1 (ko) | E형 간염 바이러스의 폴리펩티드 단편, 그를 이용한 백신 조성물 및 진단용 키트 | |
EP0787139B1 (en) | Synthetic peptides and vaccines comprising same | |
NO831098L (no) | Peptider med spesifiteten til munn- og klovsyke-virus-antigener | |
CA2018297A1 (en) | Conjugate immunogen for aids | |
CA1271717A (en) | Polypeptides useful in vaccination against enteroviruses | |
WO2002051860A2 (en) | Synthetic peptide composition as immunogens for prevention of urinary tract infection | |
WO1995031999A1 (en) | Compositions of transactivating proteins of human immunodeficiency virus | |
AU652611B2 (en) | Analogs of piscine LHRH | |
CA2143187C (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
WO1994002613A1 (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
JPH03503639A (ja) | レトロウイルスhivのペプチドpf10〜pf19、該ペプチドの合成方法、特に診断用としてのその使用 | |
HUT55035A (en) | Process for testing analogous peptides of hiv | |
JPH09500096A (ja) | ヒト免疫不全ウイルスに対する予防接種および中和抗体誘発に用いられるペプチド | |
CA2329755A1 (en) | Synthetic somatostatin immunogen for growth promotion in farm animals | |
EP0284492A1 (fr) | Nouvelles fractions peptidiques inductrices d'anticorps protecteurs contre le virus de la leucémie bovine, procédé pour l'obtention de telles fractions, leurs séquences codantes et vaccins réalisés à partir de ces fractions | |
FR2698271A1 (fr) | Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination. | |
MXPA00011752A (en) | Synthetic somatostatin immunogen for growth promotion in farm animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040519 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040908 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040929 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081008 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081008 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081008 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081008 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081008 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091008 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091008 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091008 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091008 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091008 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091008 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101008 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |